Sign in
CompletedPhase 2

A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

Key facts

Who runs it
Centre Hospitalier Universitaire de Nice
Where
France2 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
8 people enrolled
Started
18 Mar 2024
Ended
18 Aug 2026
Type of study
Interventional
Treatments tested
  • deucravacitinib
Record updated
16 October 2026

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Subject has congenital skin fragility with skin and/or mucosal blisters, a clinical phenotype of EBS-sev and a laboratory confirmed diagnosis of EBS by KRT5 and/or 14 mutation (autosomal only) OR a clinical phenotype of inflammatory ichthyosis (IC) including keratinopathic ichthyosis due to KRT1/10 mutation, ECI with identified genetic mutations (TGM5, NIPAL4, ABCA12, etc…)
  • Subject has at least a mean daily number of 4 new blisters (EBS-sev) OR an ISS > 50/128; Subject agrees not to use any topical therapies other than the investigator approved

Who cannot take part

  • Medical History and Concurrent Diseases
  • Subjects with another form of ICI ie Netherton syndrome, Kid syndrome etc
  • Infectious/Immune-related Exclusions

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment.

Read full original descriptionShow less

Participants will take treatments and have to use bullets during the study period.

The group in the trial

  • deucravacitinib treatmentTreatment being tested

    challenge-dechallenge -rechallenge design

    Treatment: deucravacitinib

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
16 October 2026